Short Course ADT for High Risk Low/Intermediate Risk ARTERA Prostate Cancer

For this study, high risk prostate cancer patients with lower risk ARTERA scores will be treated with 6 months of Androgen Deprivation Therapy (ADT) in conjunction with dose escalated radiotherapy to the prostate and nodes. Specifically, patients enrolled in this study will undergo one of several dose-escalated forms of radiotherapy which would include SBRT with or without a brachytherapy boost.

Trial Details

NCT ID
NCT07801664
Phase
PHASE2
Sponsor
NYU Langone Health
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Androgen Deprivation Therapy (ADT)
  • Radiotherapy
Locations (sample)
  • New York, New York, United States|40.71427,-74.00597

Key Eligibility Criteria

  • Ability to understand and willingness to sign a written informed consent document
  • 18 years of age or older male participants
  • Biopsy proven prostate cancer meeting at least one of the following high-risk criteria: Gleason score 8-10 OR; Baseline PSA \>20 up to and includin…
  • No imaging evidence of nodal metastases on baseline MRI/ CT of the pelvis and PET-PSMA scans

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →